vorapaxar

Known as: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate 
 

Topic mentions per year

Topic mentions per year

2010-2018
010203020102018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
BACKGROUND Vorapaxar is a protease-activated receptor-1 antagonist approved by the U.S. Food and Drug Administration (FDA) for… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2015
2015
BACKGROUND Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI while… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
Protease-activated receptor-1 (PAR1) couples the coagulation cascade to platelet activation during myocardial infarction and to… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
BACKGROUND Vorapaxar, a novel thrombin receptor antagonist, reduces cardiovascular death and recurrent thrombotic events when… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
BACKGROUND Vorapaxar is a novel antagonist of protease-activated receptor-1, the primary receptor for thrombin on human platelets… (More)
  • table 2
  • table 1
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2013
2013
BACKGROUND AND PURPOSE Vorapaxar is an antiplatelet agent that antagonizes thrombin-mediated activation of the protease-activated… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Protease-activated receptor 1 (PAR1) is the prototypical member of a family of G-protein-coupled receptors that mediate cellular… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
BACKGROUND Vorapaxar inhibits platelet activation by antagonising thrombin-mediated activation of the protease-activated receptor… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2011
2011
The aim of our study was to evaluate the pharmacology of vorapaxar (SCH 530348), an oral PAR-1 antagonist, in healthy volunteers… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?